CompLEEment-1 Canadian Correlative Sub-Study

Official Title

LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance

Summary:

Collection of tumour and blood samples from subjects enrolled in the main study (LEE011A2404) will undergo proteomic and ctDNA analysis respectively to better understand mechanisms of response and resistance to ribociclib in combination with letrozole therapy.

Trial Description

Primary Outcome:

  • Identification of proteomic biomarkers of response to ribociclib
Secondary Outcome:
  • ctDNA levels to measure the degree of mutational burden [measured as copy number]
This is a sub-study of a phase IIIb interventional study (LEE011A2404). It cannot stand alone without the parent study.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society